In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
Leigh R. Martin, a senior scientist and leader of the Fuel Cycle Chemical Technology group at ORNL, has been named a Fellow of the American Chemical Society for 2023.
ORNL hosted its fourth Artificial Intelligence for Robust Engineering and Science, or AIRES, workshop from April 18-20. Over 100 attendees from government, academia and industry convened to identify research challenges and investment areas, carving the future of the discipline.
ORNL scientists combined two ligands, or metal-binding molecules, to target light and heavy lanthanides simultaneously for exceptionally efficient separation.
Researchers from Yale University and ORNL collaborated on neutron scattering experiments to study hydrogen atom locations and their effects on iron in a compound similar to those commonly used in industrial catalysts.
While studying how bio-inspired materials might inform the design of next-generation computers, scientists at ORNL achieved a first-of-its-kind result that could have big implications for both edge computing and human health.
Oak Ridge National Laboratory researchers are developing a first-of-its-kind artificial intelligence device for neutron scattering called Hyperspectral Computed Tomography, or HyperCT.
Joseph Pickel has been elected a 2021 fellow of the American Chemical Society, or ACS. Pickel supports the Fusion and Fission Energy and Sciences Directorate as environment, safety and health
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.